VTRS · 10-Q · 2026Q3 · Full report
Nashik Supply Disruption
Viatris Inc · 2026-11-05 · Importance 46 · Surprise 42 · In source text
A February 2026 fire at Viatris’ Nashik, India oral solid dose facility temporarily suspended manufacturing, and subsequent FDA inspection observations led to remediation and further operational disruption. Product-supply disruption reduced third-quarter 2026 total revenues by an estimated $100 million; the October voluntary manufacturing suspension is expected to reduce fourth-quarter revenues by another approximately $100 million. Viatris expects production to resume in the first quarter of 2027 but does not expect to recover the 2026 lower revenues during 2027 because of the time needed to ramp production. The company recorded charges of $11.8 million in the third quarter and $98.6 million in the first nine months, primarily for damaged inventory and fixed assets and incremental manufacturing variances.
Key facts
- Viatris voluntarily suspended Nashik manufacturing in October 2026 to focus on remediation and expects production to resume in the first quarter of 2027. source
- Viatris anticipates Nashik supply disruptions will negatively affect fourth-quarter 2026 total revenues by approximately $100 million. source
- In September 2026, Viatris received notice that the FDA classified the Nashik facility inspection as OAI, which could lead to enforcement actions including a warning letter or import alert. source
- Viatris does not expect to recover in 2027 the lower revenues from 2026 because of the time needed to ramp Nashik back to full production. source
- Viatris recorded $98.6 million of charges primarily related to writing off inventory and fixed assets damaged in the Nashik manufacturing facility fire and incremental manufacturing variances for the nine months ended September 30, 2026. source
- Viatris anticipated that its Indore facility would be ready for FDA reinspection in 2026, with inspection timing determined by the FDA. source
- Manufacturing at Viatris’s Nashik facility was temporarily suspended after a fire in February 2026. source
- The FDA import alert for Viatris’s Indore oral finished dose facility affects 11 products that will no longer be accepted into the U.S. until the warning letter is lifted. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | negative | committed | -2.3% | Viatris anticipates Nashik supply disruptions will negatively affect fourth-quarter 2026 total revenues by approximately $100 million. |
| revenue | negative | contingent | — | In September 2026, Viatris received notice that the FDA classified the Nashik facility inspection as OAI, which could lead to enforcement… |